Application of β-functionalized dihydroxy-chlorins for PDT
The present invention provides biologically active compounds that can be used as photosensitizers for diagnostic and therapeutic applications, particularly for PDT of cancer, infections and other hyperproliferative diseases, fluorescence diagnosis and PdT treatment of a non-tumorous indication such as arthritis, inflammatory diseases, viral or bacterial infections, dermatological, ophthalmological or urological disorders. The compounds are of the class of β-functionalized hydroxy- and dihydroxy-chlorins having the general formula
1. A tetrapyrrolic compound comprising formula:
wherein B is selected from the group consisting of:
wherein R 1 , R 2 , R 3 and R 4 are independently selected from the group consisting of a hydrogen, an alkyl group or fluoroalkyl group comprising 1-15 carbon atoms, a phenyl ring, and a phenyl ring with one or more substituent X;
wherein R 5 is selected from the group consisting of an alkenyl comprising 2-15 carbon atoms, an alkynyl comprising 2-15 carbon atoms, a fluoroalkyl group comprising 1-15 carbon atoms, a phenyl ring and a phenyl ring with one or more substituents X;
wherein said one or more substituent X of the phenyl ring is in the ortho-, meta- or para-position;
wherein said one or more substituent X is selected from the group consisting of OCH 3 , OH, —COOH, —NH 2 , —CF 3 , —F, —COOY, —NHY, —OY, —NH—Z—COOH, —CONHCH 2 (CH 2 ) n COOH and —CO—Z—NH 2 ;
wherein the substituent Y of said substituent X is a polyethylene glycol residue containing a (CH 2 CH 2 O) n moiety with n=1-30;
wherein the substituent Z of said substituent X is selected from the group consisting of peptides and oligopeptides.
2. The tetrapyrrolic compound according to claim 1 , wherein R 1 , R 2 , R 3 and R 4 are independently selected from the group consisting of a hydrogen, an alkyl group or fluoroalkyl group comprising 1-15 carbon atoms, a phenyl ring, and a phenyl ring with one or more substituents X;
wherein said one or more substituent X of the phenyl ring is in the ortho-, meta- or para-position;
wherein said one or more substituent X is selected from the group consisting of OCH 3 , OH, —COOH, —NH 2 , —CF 3 , —F, —COOY, —NHY, —OY, —NH—Z—COOH, —CONHCH 2 (CH 2 ) n COOH and —CO—Z—NH 2 ;
wherein said substituent Y of said substituent X is a polyethylene glycol residue containing a (CH 2 CH 2 O) n moiety with n=1-30;
wherein said substituent Z of said substituent X is selected from the group consisting of peptides and oligopeptides;
wherein R 5 is selected from the group consisting of an alkenyl comprising 2-15 carbon atoms, an alkynyl comprising 2-15 carbon atoms, a fluoroalkyl group comprising 1-15 carbon atoms, and a phenyl ring substituted with one or more CF 3 -groups;
wherein said one or more CF 3 -groups are in the ortho-, meta- or para-position.
3. The tetrapyrrolic compound according to claim 1 , wherein R 1 , R 2 , R 3 and R 4 are independently selected from the group consisting of an alkyl or fluoroalkyl group comprising 4-15 carbon atoms, and a phenyl ring with one or more substituents X;
wherein said one or more substituent X is in the ortho-, meta- or para-position;
wherein said one or more substituent X is selected from the group consisting of OCH 3 , OH, —COOH, —NH 2 ;
wherein R 5 is selected from the group consisting of an alkenyl comprising 2-15 carbon atoms, an alkynyl comprising 2-15 carbon atoms, a fluoroalkyl group comprising 1-15 carbon atoms, and a phenyl ring substituted with one or more CF 3 -groups;
wherein said one or more CF 3 -groups are in the ortho-, meta- or para-position.
4. The tetrapyrrolic compound according to claim 1 , comprising formula:
wherein B is
wherein R is selected from the group consisting of an alkenyl comprising 2-15 carbon atoms, an alkynyl comprising 2-15 carbon atoms, a fluoroalkyl group comprising 1-15 carbon atoms, a phenyl ring, and a phenyl ring with one or more substituents X;
wherein said one or more substituent X is in the ortho-, meta- or para-position; wherein said one or more substituent X is selected from the group consisting of OCH 3 , OH, —COOH, —NH 2 , —CF 3 , —F, —COOY, —NHY, —OY, —NH—Z—COOH, —CONHCH 2 (CH 2 ) n COOH and —CO—Z—NH 2 ;
wherein the substituent Y of said substituent X is selected from the group consisting of a polyethylene glycol residue containing a (CH 2 CH 2 O) n moiety with n=1-30;
wherein the substituent Z of said substituent X is selected from the group consisting of peptides and oligopeptides.
5. The tetrapyrrolic compound according to claim 4 , wherein R is selected from the group consisting of an alkenyl comprising 2-15 carbon atoms, an alkynyl comprising 2-15 carbon atoms, a fluoroalkyl group comprising 1-15 carbon atoms, and a phenyl ring substituted with one or more CF 3 -groups; wherein said one or more CF 3 -groups are in the ortho-, meta- or para-position.
6. The tetrapyrrolic compound according to claim 1 , comprising formula:
wherein B is
wherein R is selected from the group consisting of an alkenyl comprising 2-15 carbon atoms, an alkynyl comprising 2-15 carbon atoms, a fluoroalkyl group comprising 1-15 carbon atoms, a phenyl ring, and a phenyl ring with one or more substituents X;
wherein said one or more substituent X is in the ortho-, meta- or para-position;
wherein said one or more substituent X is selected from the group consisting of OCH 3 , OH, —COOH, —NH 2 , —CF 3 , —F, —COOY, —NHY, —OY, —NH—Z—COOH, —CONHCH 2 (CH 2 ) n COOH and —CO—Z—NH 2 ;
wherein the substituent Y of said substituent X is selected from the group consisting of a polyethylene glycol residue containing a (CH 2 CH 2 O) n moiety with n=1-30;
wherein the substituent Z of said substituent X is selected from the group consisting of peptides and oligopeptides.
7. The tetrapyrrolic compound according to claim 6 , wherein R is selected from the group consisting of an alkenyl comprising 2-15 carbon atoms, an alkynyl comprising 2-15 carbon atoms, a fluoroalkyl group comprising 1-15 carbon atoms, and a phenyl ring substituted with one or more CF 3 -groups; wherein said one or more CF 3 -groups are in the ortho-, meta- or para-position.
8. The tetrapyrrolic compound according to claim 1 , comprising formula:
wherein B is
wherein R is selected from the group consisting of an alkenyl comprising 2-15 carbon atoms, alkynyl comprising 2-15 carbon atoms, a fluoroalkyl group comprising 1-15 carbon atoms, a phenyl ring, and a phenyl ring with one or more substituents X;
wherein said one or more substituent X is in the ortho-, meta- or para-position;
wherein said one or more substituent X is selected from the group consisting of OCH 3 , OH, —COOH, —NH 2 , —CF 3 , —F, —COOY, —NHY, —OY, —NH—Z—COOH, —CONHCH 2 (CH 2 ) n COOH and —CO—Z—NH 2 ;
wherein the substituent Y of said substituent X is selected from the group consisting of a polyethylene glycol residue containing a (CH 2 CH 2 O) n moiety with n=1-30;
wherein the substituent Z of said substituent X is selected from the group consisting of peptides and oligopeptides.
9. The tetrapyrrolic compound according to claim 8 , wherein R is selected from the group consisting of an alkenyl comprising 2-15 carbon atoms, a fluoroalkyl group comprising 1-15 carbon atoms, and a phenyl ring substituted with one or more CF 3 -groups; wherein said one or more CF 3 -groups are in the ortho-, meta- or para-position.
10. The tetrapyrrolic compound according to claim 1 , comprising formula:
11. The tetrapyrrolic compound according to claim 1 , comprising formula:
12. A pharmaceutical composition comprising a compound according to claim 1 as an active ingredient.
13. The pharmaceutical composition according to claim 12 , wherein said pharmaceutical composition is a liposomal formulation.
14. The pharmaceutical composition according to claim 12 , wherein said active ingredient is formulated in carriers selected from the group consisting of conventional liposomes, pegylated liposomes, nanoemulsions, nanocrystrals, nanoparticles, fatty emulsions, lipidic formulations, self-micro-emulsifying-drug-delivery-systems, Alpha-Feto protein (AFP), Bovine-Serum-Albumin (BSA), poly(lactic-co-glycolic acid) (PLGA), fatty emulsions, organic nanoparticles, and non-organic nanoparticles.